---
schema_version: "secwatch.filing_event.v1"
accession: "0000078003-24-000188"
form_type: "8-K"
ticker: "PFE"
cik: "0000078003"
company_name: "PFIZER INC"
filed_at: "2024-10-29T23:59:59+00:00"
generated_at: "2026-05-30T09:29:49.718732+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Pfizer Q3 revenue $17.7B (+32% YoY); raises FY 2024 guidance on revenue and EPS

## Summary
- Q3 2024 revenues of $17.7B, operational growth +32% YoY; ex-Paxlovid/Comirnaty revenue up 14% operationally.
- Reported diluted EPS $0.78 vs. ($0.42) in Q3 2023; adjusted diluted EPS $1.06 vs. ($0.17).
- Raised FY 2024 revenue guidance to $61-64B (from $59.5-62.5B) and adjusted EPS to $2.75-2.95 (from $2.45-2.65).
- Paxlovid revenue $2.7B (+$2.5B YoY); Comirnaty revenue $1.4B (+9% operational).
- Cost reduction program on track for at least $5.5B net savings; $4B expected by end of 2024.

## SEC filing metadata
- accession: 0000078003-24-000188
- form_type: 8-K
- ticker: PFE
- cik: 0000078003
- company_name: PFIZER INC
- filed_at: 2024-10-29T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/78003/000007800324000188/0000078003-24-000188-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/78003/000007800324000188/pfe-20241029.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000078003-24-000188
- JSON: https://secwatch.observer/filing/0000078003-24-000188.json
- Plain text: https://secwatch.observer/filing/0000078003-24-000188.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.